

## MAYNE PHARMA AND MITHRA ANNOUNCE US LAUNCH OF HALOETTE<sup>®</sup>, A GENERIC VERSION OF NUVARING<sup>®</sup>

---

**13 January 2023, 7:30, Adelaide, Australia and Liege, Belgium:** Mayne Pharma Group Limited (ASX: MYX) and Mithra Pharmaceuticals, SA (Euronext Brussels: MITRA) are pleased to announce the launch of HALOETTE<sup>®</sup> (etonogestrel and ethinyl estradiol) a vaginal hormonal contraceptive ring into the US market.

HALOETTE<sup>®</sup> contraceptive is a generic version of NUVARING<sup>®</sup>, a combined hormonal contraceptive flexible ring indicated for the prevention of pregnancy. According to IQVIA, NUVARING<sup>®</sup> US brand and generic sales were approximately USD 564 million for the 12 months ended November 2022.

Under the terms of the long-term license and supply agreement, Mayne Pharma will pay Mithra a milestone of EUR 1.6 million.

**Mayne Pharma's CEO Mr Shawn O'Brien said:** *"We are pleased to announce the launch of HALOETTE<sup>®</sup> in the US. This is another example of our commitment to providing women with more contraceptive choice. Mayne Pharma continues to expand its women's health portfolio with the recent launch of NEXTSTELLIS<sup>®</sup> (estetrol/drospirenone) in the US and Australia, and our new license agreement for ANNOVERA<sup>®</sup>, IMVEXXY<sup>®</sup> and BIJUVA<sup>®</sup> from TherapeuticsMD."*

**Mithra's CEO Mr Leon Van Rompay said:** *"We are pleased to start the year with the commercial launch of our affordable contraceptive alternative in the US, the world's largest pharmaceutical market. This key milestone has been reached thanks to the support of our Mithra CDMO, highlighting its unique expertise in developing and manufacturing complex pharmaceutical devices."*

\*\*\*\*\*

### For further information contact:

#### Mayne Pharma

Craig Haskins: +61 421 029 843 - [ir@maynepharma.com](mailto:ir@maynepharma.com)

#### Mithra

Benoît Mathieu (Investor): +32 473 35 80 18 - [investorrelations@mithra.com](mailto:investorrelations@mithra.com)

Maud Vanderthommen (Press): +32 473 58 61 04 – [press@mithra.com](mailto:press@mithra.com)

*Authorised for release to the ASX by the Mayne Pharma Chair*

#### About Mayne Pharma

*Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising novel and generic pharmaceuticals, offering patients better, safe and more accessible medicines. Mayne Pharma also provides contract development and manufacturing services to clients worldwide. Mayne Pharma has a 40-year track record of innovation and success in developing new oral drug delivery systems. These technologies have been successfully*

commercialised in numerous products that continue to be marketed around the world. To learn more about Mayne Pharma, please visit [maynepharma.com](http://maynepharma.com)

**About Mithra**

*Mithra (Euronext: MITRA) is a Belgian biotech company dedicated to transforming Women's Health by offering new choices through innovation, with a particular focus on contraception and menopause. Mithra's goal is to develop products offering better efficacy, safety and convenience, meeting women's needs throughout their life span. Mithra explores the potential of the unique native estrogen Estetrol in a wide range of applications in women health and beyond. Mithra also develops and manufactures complex therapeutics in the areas of contraception, menopause and hormone-dependent cancers. It offers partners a complete spectrum of research, development and specialist manufacturing at its technological platform Mithra CDMO. Active in more than 100 countries around the world, Mithra has an approximate headcount of 300 staff members and is headquartered in Liège, Belgium. [mithra.com](http://mithra.com)*

**About HALOETTE® (etonogestrel and ethinyl estradiol) vaginal ring**

*HALOETTE® contraceptive is indicated for use by females of reproductive age to prevent pregnancy. The flexible birth control ring is inserted in the vagina and is to remain in place for 3 weeks (21 days). It is removed for one week (7 days) and a new vaginal ring is inserted on the same day of the week it was inserted in the previous cycle. Etonogestrel and ethinyl estradiol vaginal ring contains a combination of a progestin and estrogen, 2 kinds of female hormones. Birth control methods that contain both an estrogen and a progestin are called combination hormonal contraceptives (CHCs).*

*HALOETTE® and NEXTSTELLIS® are registered trademarks of Novalon SA, a Mithra Pharmaceuticals company. NUVARING® is a registered trademark of Organon NV.*